Short Interest in Lucid Diagnostics Inc. (NASDAQ:LUCD) Increases By 95.2%

Lucid Diagnostics Inc. (NASDAQ:LUCD) saw a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 1,040,000 shares, a growth of 95.2% from the January 31st total of 532,700 shares. Based on an average daily volume of 531,800 shares, the days-to-cover ratio is currently 2.0 days. Approximately 4.3% of the shares of the company are sold short.

Analysts Set New Price Targets

LUCD has been the subject of several research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $2.50 target price on shares of Lucid Diagnostics in a report on Thursday, November 14th. Ascendiant Capital Markets reduced their price objective on Lucid Diagnostics from $7.25 to $7.00 and set a “buy” rating for the company in a report on Monday, December 9th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $3.00 target price on shares of Lucid Diagnostics in a research report on Thursday, November 14th. Finally, Cantor Fitzgerald dropped their price target on Lucid Diagnostics from $3.00 to $2.00 and set an “overweight” rating for the company in a report on Friday, November 15th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Lucid Diagnostics presently has a consensus rating of “Buy” and an average target price of $3.63.

Lucid Diagnostics Stock Down 1.3 %

Lucid Diagnostics stock traded down $0.02 during trading hours on Friday, hitting $1.48. The stock had a trading volume of 354,151 shares, compared to its average volume of 519,024. Lucid Diagnostics has a one year low of $0.63 and a one year high of $1.63. The stock has a market cap of $87.83 million, a price-to-earnings ratio of -1.30 and a beta of 1.49. The business’s 50 day simple moving average is $1.03 and its 200-day simple moving average is $0.92.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of LUCD. Sargent Investment Group LLC bought a new stake in shares of Lucid Diagnostics in the 4th quarter valued at $442,000. Citadel Advisors LLC acquired a new position in shares of Lucid Diagnostics in the 4th quarter valued at about $98,000. Sunbelt Securities Inc. bought a new stake in shares of Lucid Diagnostics during the 4th quarter valued at about $67,000. Geode Capital Management LLC grew its stake in Lucid Diagnostics by 30.9% during the fourth quarter. Geode Capital Management LLC now owns 279,504 shares of the company’s stock worth $229,000 after purchasing an additional 65,964 shares during the period. Finally, Lido Advisors LLC increased its holdings in Lucid Diagnostics by 40.0% in the fourth quarter. Lido Advisors LLC now owns 140,016 shares of the company’s stock worth $115,000 after purchasing an additional 40,000 shares in the last quarter. 74.01% of the stock is owned by institutional investors.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.